Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia

被引:7
作者
Persell, SD
Lloyd-Jones, DM
Baker, DW
机构
[1] Northwestern Univ, Div Gen Internal Med, Dept Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA
关键词
hypercholesterolemia; cardiovascular diseases; practice guidelines; hydroxymethylglutaryl-CoA reductase inhibitors;
D O I
10.1111/j.1525-1497.2006.00323.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Modifications to the National Cholesterol Education Program (NCEP) guidelines lowered optional low-density lipoprotein cholesterol (LDL-C) treatment goals. OBJECTIVE: We evaluated the implications of widely adopting these optional goals in clinical practice. DESIGN AND PARTICIPANTS: We performed a cross-sectional study using 1999 to 2002 data from 3,281 U.S. adults aged 20 to 79 years participating the National Health and Nutrition Examination Survey. MEASUREMENTS: The primary outcomes were the proportions of adults whose fasting LDL-C levels exceeded NCEP recommended and optional targets from 2001 and 2004. We used survey weights to estimate the size of the U.S. population exceeding targets. We examined outcomes for 4 coronary disease risk subgroups described by the NCEP. RESULTS: Low-density lipoprotein cholesterol values exceeded 2001 NCEP goals for 30.0% of adults, and 35.8% had levels above optional 2004 goals. An estimated 24,900,000 individuals (14.2%) exceeded 2001 thresholds for drug therapy, 46,200,000 (26.3%) exceeded optional 2001 thresholds for drug therapy, and 56,500,000 (32.2%) were above the optional 2004 thresholds for drug therapy. For lower, moderate, moderately high, and high-risk groups, 13.4%, 44.2%, 58.8%, and 71.8%, respectively, exceeded 2001 NCEP goals; 13.4%, 15.7%, 87.4%, and 96.0% of these groups exceeded optional 2004 thresholds for drug therapy. CONCLUSIONS: In 1999 to 2002, LDL-C levels commonly exceeded 2001 NCEP goals, especially for moderately high and high-risk individuals, and cholesterol-lowering medications were underused. Optional goals promulgated by the NCEP in 2001 and 2004 moderately increased the number of adults with LDL-C above their goal, and greatly increased the number of low, moderately high, and high-risk adults who exceeded LDL-C thresholds, for cholesterol-lowering medication.
引用
收藏
页码:171 / 176
页数:6
相关论文
共 33 条
[1]   Effects of an intensive diet and physical activity modification program on the health risks of adults [J].
Aldana, SG ;
Greenlaw, RL ;
Diehl, HA ;
Salberg, A ;
Merrill, RM ;
Ohmine, S ;
Thomas, C .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2005, 105 (03) :371-381
[2]   Screening adults for lipid disorders - Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, PS ;
Homer, CJ ;
Lieu, TA ;
Mulrow, CD ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Sox, HC ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2001, 20 (03) :73-76
[3]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[6]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[7]   Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial [J].
de Lemos, JA ;
Blazing, MA ;
Wiviott, SD ;
Lewis, EF ;
Fox, KAA ;
White, HD ;
Rouleau, JL ;
Pedersen, TR ;
Gardner, LH ;
Mukherjee, R ;
Ramsey, KE ;
Palmisano, J ;
Bilheimer, DW ;
Pfeffer, MA ;
Califf, RM ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1307-1316
[8]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[9]   New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy - Projected impact on the size, sex, and age distribution of the treatment-eligible population [J].
Fedder, DO ;
Koro, CE ;
L'Italien, GJ .
CIRCULATION, 2002, 105 (02) :152-156
[10]   Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease [J].
Federman, AD ;
Adams, AS ;
Ross-Degnan, D ;
Soumerai, SB ;
Ayanian, JZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (14) :1732-1739